Poging GOUD - Vrij

“An effective biobank provides high-quality and affordable biospecimens to drive research, aiding live-saving scientific discoveries”

BioSpectrum Asia

|

BioSpectrum Asia August 2022

Since the beginning of COVID-19, numerous biobanks have emerged to facilitate studies of the virus and disease, how it spreads, and why some people are more susceptible than others. Biobanks also provide pre-COVID samples for biological comparisons and further research. Going beyond the pandemic, biobanks play a crucial role in all disease areas. For decades now, unique collections of material, serum, tissue, and a variety of cells have been stored to help researchers understand non-communicable diseases as well. There are many critical considerations for biobanks, especially because of the safety implications of preserving sample integrity.

“An effective biobank provides high-quality and affordable biospecimens to drive research, aiding live-saving scientific discoveries”

Erik Steinfelder, Global Enterprise Relationship Lead, Thermo Fisher Scientific

To study disease risk and understand drug response numerous biobanks have emerged to facilitate genetic risk screening and pharmacogenomics in clinical research/ pandemic studies. These biorepositories preserve biospecimens like blood samples, gene pools, biopsy material, and even human microbiota. Numerous efforts are emerging to maintain biological samples through sustainable biobanking practices. Understanding that biobanks can be landmark resources for translating genomics into clinical care, and sharing insights and information critical to advancing science, Erik Steinfelder, Global Enterprise Relationship Lead at Thermo Fisher Scientific explains more about the emerging biobanking trends. Edited excerpts;

How has Asia progressed with biobanking in the last decade?

The demand for more, high-quality, and clinically annotated biospecimens will increase, primarily due to the unprecedented level of genomic, postgenomic, and personalised medicine research activities. Biobanks will need to adopt industrywide standard operating procedures, methods for quality assessment, less expensive methods for sample storage/distribution, and objective methods to manage scarce biospecimens. Public-private partnerships will also be important, as well as the number and diversity of available biospecimens, cost management, and the realisation that an effective biobank is one that provides high-quality and affordable biospecimens to drive research that aids in live-saving scientific discovery.

MEER VERHALEN VAN BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Collaborative R&D: Partnerships shaping the future of biopharma

Biotechs and pharma companies face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment. By joining forces and exploring collaborative R&D partnerships it is possible to overcome these challenges. In addition to sharing risks, they share the potential rewards when their assets move further into clinical development or come to the market.

time to read

2 mins

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Quantum Computing: Future of diagnostics is being coded today

A silent revolution is being built at the intersection of biology and quantum physics. After decades of pushing the boundaries of diagnostics with advanced imaging and AI, we are now approaching a hard computational wall. For complex conditions like Alzheimer's, Parkinson's, and many cancers, the interacting variables of genomics, proteomics, and real-world patient data are simply too vast for classical computers to master. This limitation caps the ability to move from merely spotting correlations to uncovering true causation. Unlike traditional AI, quantum computing can simulate underlying physical systems to derive precise solutions. The transition from correlational analysis to causal simulation will enable a more valuable and advanced frontier in diagnostics.

time to read

4 mins

BioSpectrum Asia Sep 2025

BioSpectrum Asia

First Pacific woman to serve as public health director in NZ

The Ministry of Health in New Zealand (NZ) has appointed Dr Corina Grey as the new Director of Public Health this year, a landmark appointment for Pacific leadership.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

Bio-Rad appoints Rajat Mehta as Executive Vice President of Global Commercial Operations

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, has announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Hugel launches botulinum toxin Letybo in Malaysia

South Korea-based Hugel Inc., a leading global medical aesthetics company, has officially launched its botulinum toxin product Letybo in Malaysia - an emerging market for medical aesthetics in Southeast Asia.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Australia designs smart wound monitor to improve chronic infection care

Researchers from Australia's RMIT University have developed a wearable wound monitoring device with integrated sensors that could reduce infection risks by minimising the need for frequent physical contact.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

Revvity unveils innovative reagent technology to accelerate therapeutics development

US-based Revvity, Inc. has announced the launch of pHSense reagents, a powerful technology designed to advance internalisation studies in drug discovery.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Sanofi acquires next-gen vaccine biotech Vicebio for $1.6 B

Vicebio, a biopharmaceutical company with operations in Australia, UK and Belgium, has entered an exclusive, definitive agreement to be acquired by Sanofi.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

HOSMAC signs MoU with Gulf Medical University to strengthen healthcare education

HOSMAC, Asia's leading hospital planning, design, and management consultancy, has signed a Memorandum of Understanding (MoU) with Gulf Medical University (GMU), Ajman, UAE, to serve as an industry partner.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

Jessica Cowden takes charge as Deputy Director General of CARE unit at IVI

Dr Jessica Cowden has been appointed Deputy Director General of the Clinical, Assessment, Regulatory, Evaluation (CARE) unit at South Korea-headquartered International Vaccine Institute (IVI). She will continue to be based at IVI's Europe Regional Office in Stockholm, Sweden.

time to read

1 min

BioSpectrum Asia Sep 2025

Translate

Share

-
+

Change font size